Printer Friendly


 ROCKVILLE, Md., May 27 /PRNewswire/ -- Cryomedical Sciences, Inc. (NASDAQ-NMS: CMSI), announced today results of two separate studies using its CMS AccuProbe System, which utilizes "super-cooled" (-180 degrees Centigrade) liquid nitrogen circulating through disposable probes to freeze and destroy prostate and other cancerous tumors. The studies followed earlier reports indicating that cryosurgery may provide urologists with another tool for use in prostate cancer surgery.
 The new data was presented at the American Urological Association's annual conference earlier this month, and summaries appear in the association's April 1993 Journal of Urology. Both studies were conducted at Allegheny General Hospital in Pittsburgh, and reported by Dr. Jeffrey K. Cohen, Dr. G. Onik and Dr. R. Miller of the hospital.
 In Patients Failing Radiation Therapy
 The study focused on 14 prostate cancer patients on whom the freezing technique was used after radiation therapy had failed. Biopsies were performed and PSA (Prostate Specific Antigen) levels were assessed in the first seven patients who had reached three months post- operatively at the time the abstract was submitted. None of the seven had evidence of carcinoma and PSA values had dropped. PSA is a test that usually indicates the presence of prostate cancer. The mean hospital stay was only three days and morbidity (side effects) was minimal.
 "In summary, this application of cryosurgery can be delivered with minimal morbidity," the authors concluded. "Biopsy data confirms the change from malignancy to fibrous scar. This may provide another (option) for this group of patients." The reduced morbidity achieved by cryosurgery is due to the minimally invasive procedure and the fact that the destroyed tissue is absorbed by the body and does not need to be removed surgically.
 In Patients as a Primary Surgical Procedure
 The objective of the second study was to evaluate the efficacy of cryosurgery in treating patients with varying stages of prostate cancer who were not radiation failures or who had not had radical proctectomies. In this study, the first group of 50 patients underwent the procedure and were followed to obtain three-month biopsies and assess PSA levels. Of these, 40 patients, or 80 percent, had negative biopsies (no signs of cancer) and PSA levels which had dropped. None of the patients were incontinent and morbidity was minimal. The mean hospital stay was only two days. These results compare with only 50 percent to 70 percent negative-biopsy rates in patients who undergo radical prostatectomy and 10 percent to 40 percent in patients who were administered radiation therapy, as reported in the medical literature.
 According to recent reports, some doctors are advocating a "watchful waiting" approach as opposed to radical prostatectomy or radiation therapy, given the difficulty in managing the disease and the substantial side effects resulting from these procedures. Commenting on these reports, Cohen, professor of surgery at Allegheny General Hospital, said, "While this approach could make sense in some cases, if surgical intervention can be obtained with reduced morbidity, such as may be the case with cryosurgery, most patients and doctors would not choose to simply leave the cancer."
 J.J. Finkelstein, Cryomedical Sciences president and CEO, said: "We are extremely encouraged by the results achieved in these and other studies involving the use of the CMS AccuProbe System with patients suffering from prostate cancer. If these results hold true over time, it would be a major accomplishment to offer the medical community a new surgical modality for prostate cancer that produces few side effects and is approximatley 50 percent of the cost of traditional surgery." He noted that Since October 1991, the CMS AccuProbe has been used on approximately 500 patients with cancer of the prostate, liver, brain and other organs.
 Cryomedical Sciences, Inc., is engaged in the research, development, manufacturing and marketing of products in the field of hypothermic (low temperature) medicine. Cryomedical Sciences introduced the CMS AccuProbe System in June 1992. The company is also investigating blood substitute solutions which may permit "bloodless" surgery in the future and improve organ preservation capabilities and transplantation techniques.
 -0- 5/27/93
 /NOTE: AccuProbe is registered trademark./
 /CONTACT: J.J. Finkelstein, president and chief executive officer, Cryomedical Sciences, 301-417-7070; or Marianne Steward or Jerry Miller of the Financial Relations Board, 212-661-8030, for Cryomedical Sciences/

CO: Cryomedical Sciences, Inc. ST: Maryland IN: MTC SU:

IH-TW -- DC015 -- 2925 05/27/93 11:51 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 27, 1993
Previous Article:/C O R R E C T I O N -- USA TODAY/

Related Articles
ENDOcare Announces 510(K) Clearance for Temperature Monitoring Probes
ENDOcare Completes $7.8 Million Private Placement
Endocare Responds to Press Release
ENDOcare Expands Manufacturing Capacity
ENDOcare Receives Key Patent For Cryosurgical Temperature Monitoring System
Endocare Develops Low Cost Treatment Device For BPH
EDAP TMS S.A. and HealthTronics Surgical Services, Inc. Announce Finalization Of Agreement for Ablatherm(R) in the U.S.A. Allows HealthTronics to...
EDAP TMS S.A. Announces Purchase of Ablatherm by Tor Vergata Polyclinic in Rome, Italy.
Survey Shows At-Risk Men Lacking In Prostate Cancer Knowledge.

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters